Accendra Health (NYSE:ACH) Rating Lowered to "Hold" at Robert W. Baird

Key Points

• Robert W. Baird downgraded Accendra Health from “strong buy” to “hold,” while the broader analyst consensus is “Reduce” with an average price target of $2.50.
• Accendra Health reported quarterly EPS of -$0.19, missing the $0.13-loss estimate, on revenue of $613.23 million; the company continues to report negative margins and returns on equity.
• Shares opened at $1.24, near the 12-month low of $1.20 and well below the 50-day moving average of $3.13, giving the company a market capitalization of approximately $95 million.

Accendra Health (NYSE:ACH - Get Free Report) was downgraded by analysts at Robert W. Baird from a "strong-buy" rating to a "hold" rating in a note issued to investors on Tuesday,Zacks.com reports.

A number of other equities research analysts have also issued reports on ACH. UBS Group upped their target price on Accendra Health from $3.00 to $4.50 and gave the company a "neutral" rating in a research note on Tuesday, May 12th. Citigroup downgraded Accendra Health from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $4.50 to $1.50 in a research report on Monday. Zacks Research raised Accendra Health from a "strong sell" rating to a "hold" rating in a report on Tuesday, April 21st. Finally, Weiss Ratings downgraded Accendra Health from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday, August 6th. Four research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Accendra Health has a consensus rating of "Reduce" and an average target price of $2.50.

Accendra Health Price Performance

NYSE:ACH opened at $1.24 on Tuesday. The stock has a market cap of $94.96 million, a P/E ratio of -0.32, a P/E/G ratio of 2.16 and a beta of 1.58. The company's 50-day simple moving average is $3.13. Accendra Health has a twelve month low of $1.20 and a twelve month high of $5.85.

Accendra Health (NYSE:ACH - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The business had revenue of $613.23 million during the quarter. Accendra Health had a negative net margin of 11.41% and a negative return on equity of 4.24%. As a group, sell-side analysts predict that Accendra Health will post 0.31 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Walleye Capital LLC acquired a new stake in shares of Accendra Health in the first quarter worth $27,000. Hsbc Holdings PLC acquired a new position in shares of Accendra Health during the 1st quarter valued at $34,000. Abel Hall LLC acquired a new position in shares of Accendra Health during the 1st quarter valued at $44,000. Keybank National Association OH purchased a new stake in Accendra Health during the 1st quarter worth $46,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Accendra Health during the 1st quarter worth $50,000.

Accendra Health Company Profile

Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source